



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PI3K α -IN-23

Cat. No.:	HY-163501
Molecular Formula:	C ₂₈ H ₂₇ N ₃ O ₃
Molecular Weight:	453.53
Target:	PI3K; Akt
Pathway:	PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PI3K α -IN-23 (Compound 9) is an inhibitor of PI3K α H1047R ^[1] .															
IC₅₀ & Target	PI3K α -H1047R															
In Vitro	PI3K α -IN-23 inhibits pAKT phosphorylation in cell with IC ₅₀ =1 nM-500 nM (T-47D); >15 μ M (SKBR3), respectively ^[1] . PI3K α -IN-23 can inhibit cell proliferation with EC ₅₀ =500 nM-2 μ M (T-47D); 2 μ M-15 μ M (SKBR3) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.															
In Vivo	<p>Pharmacokinetic Analysis in PK-Mouse^[1]</p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>Cl (mL/min/kg)</th> <th>AUC_{last} (h·ng/mL)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>1</td> <td>35.7</td> <td>464</td> <td>/</td> </tr> <tr> <td>p.o.</td> <td>10</td> <td>/</td> <td>1950</td> <td>41</td> </tr> </tbody> </table> <p>IV Vehicle: 20% PEG400 / 20% PG / 60% of 20% HPβCD solution in water PO Vehicle: 30% SBE3CD in water MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	Route	Dose (mg/kg)	Cl (mL/min/kg)	AUC _{last} (h·ng/mL)	F (%)	i.v.	1	35.7	464	/	p.o.	10	/	1950	41
Route	Dose (mg/kg)	Cl (mL/min/kg)	AUC _{last} (h·ng/mL)	F (%)												
i.v.	1	35.7	464	/												
p.o.	10	/	1950	41												

REFERENCES

[1]. James F et al. Preparation of ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as PI3K inhibitors for the treatment of cancer. World Intellectual Property Organization, WO2024064024 A1 2024-03-28

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA